Why the study?
Does a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy reduce bleeding and prevent thrombotic events in patients undergoing primary PCI?
Population
Patients undergoing primary PCI
Comparison
CYP2C19 genotype-guided strategy for selection… vs Standard treatment with ticagrelor or prasugrel
Design
RCT
Follow-up
12 months
Authors
Loading...
Supports CYP2C19-guided P2Y12 selection in primary PCI to reduce bleeding; extends RCT evidence for precision antiplatelet therapy.
Does a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy reduce bleeding and prevent thrombotic events in patients undergoing primary PCI?
A CYP2C19 genotype-guided strategy for P2Y12 inhibitor selection in primary PCI is noninferior for preventing thrombotic events while significantly reducing bleeding compared to standard therapy.
Claassens et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: